Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate

European Journal of Endocrinology

Volumn 147, Issue 4, 2002, Pages 479-484

  Azzouzi, Abdel Rahmene ^a   Cochand Priollet, Beatrix ^a   Mangin, Philippe ^a   Fournier, Georges ^a   Berthon, Philippe ^a   Latil, Alain ^a   Cussenot, Olivier ^a  

^a Parc Scientifique de Luminy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; CYTOCHROME P450 17; ESTROGEN; STEROID 5ALPHA REDUCTASE;

ALLELE; ARTICLE; AUTOCRINE EFFECT; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOCRINE FUNCTION; GENETIC CORRELATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMEOSTASIS; HORMONE ACTION; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; ORGAN WEIGHT; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REGULATOR GENE; SIGNAL TRANSDUCTION;

EID: 0036772923     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470479     Document Type: Article

References (20)

1. Boyle P, Gu PL, Jacobsen S, Ogawa O, Oishi K, O'Relly P et al. Epidemiology and natural history of benign hyperplasia. In 4th International Consultation on Benign Prostatic Hyperplasia (BPH), pp 25-59. Eds L Denis, K Griffiths & S Khoury. Plymouth, UK: Health Publication Distributors Ltd, 1998.
2. Berry SJ, Coffey DS, Walsh PC & Ewing LL. The development of human benign hyperplasia with age. Journal of Urology 1984 132 474-479.
3. Henderson BE & Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000 21 427-433.
4. Novelli G, Margiotti K, Sangiuolo F & Reichardt JK. Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2001 2 65-72.
5. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, de La Rosette JJ et al. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. European Urology 2000 37 234-238.
6. Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S & Tsujimoto G. Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. British Journal of Pharmacology 1996 118 1403-1408.
7. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999 53 121-125.
8. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1999 41 253-257.
9. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Research 2000 60 5710-5713.
10. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC & Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Research 1995 55 3973-3975.
11. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Research 1997 57 1020-1022.
12. Brentano ST, Picado-Leonard J, Mellon SH & Miller WL. Tissue-specific cyclic adenosine 3′, 5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Molecular Endocrinology 1990 4 1972-1979.
13. Kadonaga JT, Jones KA & Tijian R. Promoter-specific activation of RNA polymerase II transcription by SP1. Trends in Biochemical Sciences 1986 11 20-23.
14. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics 1994 3 1873-1876.
15. Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzl G, Madersbacher S et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. International Journal of Cancer 2000 87 434-437.
16. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P & Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998 8 43-48.
17. Siegelmann-Danieli N & Buetow KH. Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer risk. British Journal of Cancer 1999 79 456-463.
18. Huggins C & Hodges CV. Studies on prostatic cancer. Cancer Research 1941 1 293-297.
19. Meikle AW, Stephenson RA, Lewis CM, Wiebke GA & Middleton RG. Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins. Prostate 1997 33 105-111.
20. Schatzl G, Gsur A, Bernhofer G, Haidinger G, Hinteregger S, Vutuc C et al. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology 2001 57 567-572.